Quick answer: Food sensitivity testing — particularly IgG-based panels — generates more controversy among physicians than almost any other functional medicine tool, yet IgG4 food antibodies in the clinical context of a systematic elimination-reintroduction protocol have helped thousands of patients identify dietary drivers of IBS, migraines, eczema, fatigue, and joint pain that standard allergy testing misses entirely. Understanding what each type of food reactivity test actually measures — and what it doesn’t — is essential for using these tools effectively and avoiding misinterpretation.
The Three Types of Food Reactivity: IgE, IgG, and Non-Immunological
Food reactions involve distinct immunological and non-immunological mechanisms that require different testing approaches:
IgE-mediated food allergy (Type I hypersensitivity): The classical food allergy — immediate onset (minutes to 2 hours), potentially life-threatening, involving mast cell degranulation triggered by IgE antibodies bound to the high-affinity FcεRI receptor. Symptoms: urticaria, angioedema, bronchospasm, anaphylaxis. Testing: skin prick test (SPT) and specific IgE serum testing (ImmunoCAP, RAST) — gold standard with well-established sensitivity and specificity. The 8 major food allergens (peanuts, tree nuts, fish, shellfish, milk, eggs, wheat, soybeans) account for 90% of IgE-mediated reactions. Confirmed by double-blind placebo-controlled oral food challenge (DBPCFC) — the ultimate diagnostic standard. This category is NOT what functional medicine food sensitivity testing addresses.
IgG-mediated food sensitivity: Delayed-onset reactions (2-72 hours after consumption), involving IgG antibodies — primarily IgG4, the “blocking” antibody class associated with immune tolerance development. The controversy: IgG4 in immunology is classically viewed as a tolerance marker rather than a pathogenic antibody — yet in the clinical setting, patients with elevated IgG4 to specific foods often show symptom improvement when those foods are eliminated. The resolution: IgG4 elevations likely identify foods being consumed regularly in the context of intestinal permeability, where dietary antigens cross the gut barrier and stimulate immune responses that wouldn’t occur in an intact gut. Eliminating those foods reduces antigen exposure and immune activation while the underlying permeability is repaired.
Non-immunological food reactions: Enzyme deficiencies (lactase deficiency — lactose intolerance; sucrase-isomaltase deficiency), pharmacological reactions (tyramine sensitivity, histamine intolerance — DAO enzyme deficiency), FODMAPs reactions (fermentable oligosaccharides, disaccharides, monosaccharides, and polyols causing osmotic and fermentative symptoms in SIBO/IBS), and pseudoallergic reactions to salicylates and benzoates. These do not involve antibodies and are not detected by IgE or IgG testing.
What IgG Food Sensitivity Testing Actually Measures
IgG food sensitivity panels (Cyrex Array 10, US BioTek, Genova Diagnostics, ELISA/ACT Biotechnologies) measure serum IgG antibodies — most commonly IgG1-4 subclasses, either combined or separated — to 90-250+ food antigens. The key clinical and scientific considerations:
What elevated IgG4 indicates: Regular antigen exposure + immune system awareness + potential intestinal permeability allowing antigen translocation. High IgG4 to a food you rarely eat is less clinically meaningful than high IgG4 to a food consumed daily. The clinical utility is identifying which of the patient’s regularly consumed foods is generating the most significant immune response — suggesting an elimination trial is warranted for those specific foods.
What elevated IgG4 does NOT indicate: (1) Confirmed causation of symptoms — the test identifies candidates for elimination, not proven culprits. (2) Permanent intolerance — IgG4 levels decline when a food is eliminated for several months, and food can often be successfully reintroduced after gut repair. (3) Anaphylaxis risk — IgG4 does not activate mast cells via FcεRI and does not cause acute allergic reactions.
The major criticism and its rebuttal: Medical societies (AAAI, ACAAI) state that IgG food testing “has no diagnostic value” and represents a normal immune response to food exposure. This criticism is valid for using IgG4 as a standalone diagnostic marker — elevated IgG4 to milk doesn’t diagnose milk sensitivity. However, the clinical use of IgG testing in functional medicine is not standalone diagnosis but systematic hypothesis generation: use the panel to prioritize the foods for a structured elimination-reintroduction protocol, then confirm or refute through symptom response. Used this way, IgG testing is a hypothesis generation tool, not a definitive diagnostic test.
The Evidence for Food Sensitivity Elimination in Clinical Conditions
Despite the testing controversy, the evidence for dietary elimination in specific conditions is substantial:
IBS: The FODMAP-reduced diet is now first-line treatment for IBS-D, endorsed by major gastroenterology societies. Halmos 2014 Gastroenterology (n=30, RCT crossover): low-FODMAP diet reduced IBS symptoms in 76% of patients. The elimination is based on carbohydrate fermentation patterns, not immunological reactions — yet it demonstrates that dietary triggers are real and measurable. Separate from FODMAP, specific IgG-guided elimination has been studied: Atkinson 2004 Gut (n=150, RCT): IgG-guided food elimination improved IBS symptom score by 26% vs 10% for sham diet (p<0.001). This remains one of the better-designed IgG elimination trials and supports the hypothesis-generation utility of IgG testing.
Migraine: Alpay 2010 Cephalalgia (n=30, RCT): IgG-guided elimination reduced headache frequency by 29 days over 6 weeks compared to sham diet. Arroyave Hernández 2007 Revista Alergia México demonstrated significant migraine reduction with IgG-guided elimination. The rationale: trigeminovascular activation involves neurogenic inflammation, and dietary antigens activating mucosal immune responses may contribute to the inflammatory milieu lowering the migraine threshold.
Eczema/atopic dermatitis: Beyond IgE-mediated eczema, non-IgE food reactions contribute significantly — particularly to childhood eczema. Eigenmann 1998 J Allergy Clin Immunol demonstrated food protein-specific lymphocyte responses in atopic dermatitis. Cow’s milk protein, eggs, wheat, and soy are the most common dietary triggers in pediatric eczema — overlapping with but distinct from IgE sensitization patterns.
Rheumatoid arthritis and autoimmune conditions: Hafström 2001 (Rheumatology) demonstrated a vegan diet reduced RA disease activity — possibly via reduced antigenic load from animal proteins. Sköldstam 1999 Scand J Rheumatol found fasting followed by vegetarian diet reduced CRP and inflammation in RA. Dietary modification is not curative in established RA but may reduce inflammatory burden and medication requirements.
Non-celiac gluten sensitivity (NCGS): A distinct entity from celiac disease — occurring in an estimated 6% of the US population according to Sapone 2012 BMC Medicine. Characterized by intestinal and extra-intestinal symptoms triggered by gluten ingestion without celiac disease or wheat allergy. Diagnosis requires: (1) negative celiac serology (tTG-IgA, EMA), (2) negative HLA-DQ2/DQ8 or normal small bowel biopsy, (3) symptom resolution on gluten elimination, (4) symptom recurrence on double-blind gluten challenge. Mechanisms may include innate immune activation (IL-8, eosinophil migration — Sapone 2011), rather than adaptive immunity as in celiac.
Advanced Food Reactivity Testing: Beyond Basic IgG
Several advanced testing options provide additional clinical information beyond standard IgG panels:
Cyrex Array 2 (Intestinal Antigenic Permeability Screen): Measures antibodies to tight junction proteins (zonulin, occludin, claudin-3) and lipopolysaccharide (LPS) — distinguishing the cause of intestinal permeability (LPS-driven bacterial permeability vs tight junction disruption). Cyrex Array 3X (Wheat/Gluten Proteome Reactivity) measures antibodies to 24 wheat and gluten proteins beyond the gliadin fractions tested in standard celiac panels — identifying reactivity to native vs deamidated gliadin, non-gliadin wheat proteins (wheat germ agglutinin, gluteomorphin, wheat microbiome antigens). Patients with strongly positive Cyrex Array 3X and negative standard celiac panels have a clinically meaningful immune response to wheat components that standard testing misses.
ALCAT test: Measures whole blood cell morphology changes in response to food extracts — a cellular response test claimed to identify innate immune food reactions distinct from IgG-mediated mechanisms. More controversial than IgG testing; limited high-quality RCT evidence for clinical utility beyond IBS. Some practitioners find it useful for identifying reactions not captured by antibody-based testing.
ELISA/ACT lymphocyte response testing: Measures delayed hypersensitivity responses via lymphocyte activation — distinct from both IgE and IgG mechanisms, capturing T-cell mediated Type IV hypersensitivity reactions. Theoretical advantage: captures cell-mediated reactions not detected by antibody testing. Limited published clinical validation compared to IgE/IgG testing.
Mucosal IgA testing (secretory IgA to specific foods): Some comprehensive stool panels include fecal IgA to specific food antigens — particularly anti-gliadin IgA and anti-casein IgA. These capture local gut immune responses that may not be reflected in serum antibody levels. Anti-gliadin sIgA can be positive in patients with NCGS who have normal serum anti-gliadin IgA.
Celiac Disease: The Diagnostic Gold Standard
Celiac disease requires specific attention in any food sensitivity evaluation — it is an underdiagnosed autoimmune condition (affecting 1% of the population, with most cases undiagnosed) with significant long-term health consequences if untreated.
Celiac screening: tissue transglutaminase IgA (tTG-IgA) plus total IgA (IgA deficiency falsely lowers tTG-IgA — present in 2-3% of celiac patients). If total IgA is low, use tTG-IgG or deamidated gliadin peptide (DGP) IgG instead. HLA-DQ2 and DQ-8 genotyping: 95% of celiac patients carry at least one allele. Negative HLA-DQ2/DQ8 essentially rules out celiac disease (high negative predictive value). Positive serology requires small bowel biopsy (duodenal samples, ≥4 biopsies per Marsh criteria) for confirmation — taken while still consuming gluten.
The critical functional medicine contribution: celiac disease has many “silent” presentations without classic GI symptoms — presenting as iron deficiency anemia (malabsorption), osteoporosis (calcium/vitamin D malabsorption), infertility, peripheral neuropathy, ataxia (gluten ataxia — Hadjivassiliou 2003), liver enzyme elevation, thyroid disease (Ventura 2000 demonstrated 10× thyroid autoantibody prevalence in celiac), and dermatitis herpetiformis. Systematic celiac screening in any patient with unexplained iron deficiency, osteoporosis, infertility, or autoimmune thyroid disease is essential functional medicine practice.
The Elimination-Reintroduction Protocol: The Gold Standard for Food Sensitivity Confirmation
Regardless of which laboratory test identifies food reactivity candidates, the elimination-reintroduction protocol remains the clinical gold standard for confirming true food sensitivity. Laboratory testing generates the hypothesis; elimination-reintroduction confirms it.
Phase 1 — Elimination (3-4 weeks minimum, 6 weeks preferred): Complete elimination of all suspect foods simultaneously. Most IgG-mediated symptoms require 2-4 weeks to fully resolve; shorter elimination periods miss delayed reactions. The most common foods eliminated in a comprehensive protocol: gluten (all wheat, barley, rye, contaminated oats), dairy (all cow’s milk proteins — casein and whey), eggs, soy, corn, peanuts, tree nuts, shellfish/fish (the top IgE allergens), and any foods showing strong IgG positivity. For NCGS specifically, gluten elimination alone is the primary intervention.
Phase 2 — Symptom assessment: Systematic documentation of symptom changes using validated tools (IBS-SSS, MIDAS for migraine, SCORAD for eczema, patient-reported outcome measures). Symptom improvement during elimination confirms that dietary triggers are contributing — and establishes the baseline for reintroduction comparison. If no symptom improvement occurs with complete elimination, food sensitivity is unlikely to be the primary driver and other causes (SIBO, dysbiosis, non-dietary inflammation) should be investigated.
Phase 3 — Systematic reintroduction: One food group reintroduced every 3 days, consuming a significant portion (at least 1-2 servings twice daily for 2 days), then 1 day off, then monitoring symptoms for an additional 2-3 days (to capture delayed reactions up to 72 hours). Document symptom changes for each food challenge. A food that produces symptom recurrence is confirmed as a current sensitivity. Foods that are tolerated are reintroduced to the regular diet.
Phase 4 — Gut repair during and after elimination: The elimination phase creates the therapeutic window for gut repair protocols — addressing intestinal permeability, dysbiosis, and digestive insufficiency. As gut integrity is restored and the underlying drivers are addressed, tolerance to previously reactive foods often develops over 6-12 months. Many food sensitivities are transient, not permanent — they reflect the current state of gut health rather than lifelong fixed intolerances.
Common Foods, Common Reactions: A Clinical Guide
Gluten: Implicated in celiac disease (1% of population), wheat allergy (0.5%), and NCGS (estimated 6%). Non-celiac gluten sensitivity symptoms extend well beyond GI — neurological symptoms, fatigue, joint pain, mood disturbance. Gluten also contains WGA (wheat germ agglutinin) — a lectin that directly binds to intestinal epithelial cells and disrupts tight junctions independently of immune mechanisms (Vojdani 2009).
Dairy: Casein (especially A1 beta-casein vs A2 beta-casein) and whey are distinct antigens. A1 beta-casein (dominant in conventional US cow’s milk) is cleaved by digestive enzymes into beta-casomorphin-7 (BCM-7) — an opioid peptide with potential neurological effects. Trivedi 2021 European Journal of Nutrition RCT demonstrated significantly lower GI symptoms and superior cognitive function with A2 milk vs conventional A1 milk in subjects with self-reported dairy intolerance, without affecting lactose-digesting capacity. Casein IgG4 reactivity is among the most common food sensitivities detected on IgG panels.
Eggs: Egg white proteins (ovalbumin, ovomucoid) are the primary reactive components. IgG4 to egg white is extremely common on food sensitivity panels — partly reflecting frequency of consumption, partly reflecting genuine immune activation in leaky gut states. Symptom categories: IBS, eczema, migraine.
FODMAPs: Not an immunological reaction — osmotic and fermentative. Fructose (apple, mango, honey), lactose (dairy), fructans (wheat, garlic, onion), galactooligosaccharides (legumes), polyols (stone fruits, artificial sweeteners). The low-FODMAP diet is managed by a registered dietitian experienced in FODMAP — it is a sophisticated dietary intervention, not simply “avoiding sugar.”
Nightshades (solanaceae): Tomatoes, peppers, eggplant, potatoes — contain solanine and other alkaloids that may inhibit cholinesterase and contribute to joint inflammation in sensitive individuals. Sahelian 2014 Rheumatology review described joint symptom improvement with nightshade elimination in a subset of arthritis patients. Evidence is anecdotal but clinically observed frequently enough to warrant trial elimination in refractory inflammatory arthritis.
Food Sensitivity Testing at The Private Practice
Dr. Biernacki’s food sensitivity evaluation contextualizes IgG testing within a comprehensive assessment of gut health — combining microbiome testing, intestinal permeability markers, and SIBO breath testing with the food reactivity panel to understand why sensitivities are present, not just which foods are reactive. The result is a targeted elimination-reintroduction protocol supported by gut repair interventions that address the underlying permeability and dysbiosis — the goal being food tolerance restoration, not permanent restriction.
If you’ve been suffering from IBS, migraines, eczema, joint pain, fatigue, or mood symptoms without a satisfying explanation, food sensitivity evaluation may identify dietary contributors that standard testing has missed. To schedule a comprehensive food sensitivity and gut health evaluation with Dr. Biernacki, call (810) 206-1402 or visit theprivatepractice.co.
Frequently Asked Questions About Food Sensitivity Testing
Q: Is IgG food testing scientifically valid?
A: The answer depends on how it is used. IgG4 food antibodies are not a standalone diagnostic marker for food sensitivity — medical societies are correct that elevated IgG4 alone doesn’t diagnose “food intolerance.” However, used as a hypothesis-generation tool to guide a systematic elimination-reintroduction protocol, IgG testing provides more targeted information than eliminating all possible foods simultaneously. The Atkinson 2004 Gut RCT demonstrated IgG-guided elimination improved IBS symptom scores by 26% vs 10% for sham diet — suggesting clinical utility when combined with confirmation through elimination and reintroduction.
Q: Can I have a food sensitivity to something I eat every day?
A: Yes — this is the most clinically counterintuitive aspect of delayed food sensitivity. Daily consumption of a reactive food produces continuous, low-grade immune activation and symptoms that become the patient’s baseline — they’ve forgotten what it feels like without those symptoms. The relationship between daily consumption and IgG4 elevation is direct: the more frequently a food is consumed in the context of intestinal permeability, the higher the IgG4 level tends to be. This is why the most reactive foods on IgG panels are often the patient’s dietary staples — wheat, dairy, eggs — because these are consumed most frequently.
Q: How is non-celiac gluten sensitivity different from celiac disease?
A: Celiac disease is an autoimmune condition with specific genetic (HLA-DQ2/DQ8), serological (tTG-IgA, EMA), and histological (villous atrophy, Marsh criteria) diagnostic criteria. NCGS lacks these markers — it is diagnosed by exclusion of celiac and wheat allergy followed by symptom improvement on gluten elimination and recurrence on double-blind challenge. Mechanistically, NCGS appears to involve innate immune activation (IL-8, eosinophil migration) rather than the adaptive immunity-driven autoimmune cascade of celiac disease. Both require strict gluten elimination for symptom management, though NCGS may carry less severe long-term consequences than untreated celiac disease.
Q: How long does it take for food sensitivity symptoms to resolve after elimination?
A: Most IgE-mediated allergy symptoms resolve within 24 hours of elimination. Delayed (IgG-mediated) reactions require longer: GI symptoms typically improve within 1-2 weeks; headaches and migraines often improve within 2-3 weeks; skin conditions (eczema, psoriasis) may require 4-8 weeks; joint symptoms 3-6 weeks. Cognitive and mood symptoms often show gradual improvement over 3-6 weeks as neuroinflammation resolves. If no improvement occurs after 4-6 weeks of complete, strict elimination, food sensitivity is unlikely to be the primary driver and further investigation is warranted.